391-405 of 835
Higher Risk, Lowered Age: New Colorectal Cancer Screening Guidelines
Project Oncology®Higher Risk, Lowered Age: New Colorectal Cancer Screening Guidelines
How Physician-Focused APMs Aim to Overcome Challenges
Perspectives with the AMAHow Physician-Focused APMs Aim to Overcome Challenges
Smart Phones, Genomics and AI: Health Care's Next Frontier in Personalized Medicine
Conversations on Health CareSmart Phones, Genomics and AI: Health Care's Next Frontier in Personalized Medicine
The Quality Payment Program in 2019: What to Know About Upgrading Your EHR
Perspectives with the AMAThe Quality Payment Program in 2019: What to Know About Upgrading Your EHR
What Are Your Quality Reporting Options?
Perspectives with the AMAWhat Are Your Quality Reporting Options?
FDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
FDA Drug Information UpdatesFDA Warns of Serious Immune Reaction with Seizure/BPD Medicine Lamotrigine (Lamictal)
- advertisement
Skinny Liver: A Closer Examination of Fatty Liver Disease
NutritionEdgeSkinny Liver: A Closer Examination of Fatty Liver Disease
Sustainable Beef Production: An Analysis of Cattle Industry Sustainability & Its Economic Impact
NutritionEdgeSustainable Beef Production: An Analysis of Cattle Industry Sustainability & Its Economic Impact
Effects of Medicaid Access on Clinical Outcomes: Does Coverage Improve Health?
Clinician's RoundtableEffects of Medicaid Access on Clinical Outcomes: Does Coverage Improve Health?
Addressing the Challenges of Influenza Vaccination on US College Campuses
Everyday Family MedicineAddressing the Challenges of Influenza Vaccination on US College Campuses
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Project Oncology®FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
- advertisement
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Drug Information UpdatesFDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
FDA Drug Information UpdatesFDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk
STI Screening & Counseling Strategies for Transgender Patients
Clinician's RoundtableSTI Screening & Counseling Strategies for Transgender Patients
